TL;DR
This paper explores the application of transformer-based language models (LLMs) for predicting patient response to cancer immunotherapy, a task traditionally dominated by tabular machine learning methods. The authors demonstrate that LLMs, particularly when fine-tuned with domain-specific knowledge, can significantly improve prediction accuracy, especially in few-shot learning scenarios where limited patient data is available.
What Problem Does This Paper Address?
Predicting a patient's response to cancer immunotherapy is crucial for effective treatment. While antibodies targeting PD-1/PD-L1 have shown promise, not all patients benefit, highlighting the need for accurate prognostic models. Current clinical prediction models often rely on tabular data and traditional machine learning techniques. However, the recent success of transformer architectures, the backbone of large language models (LLMs), in various domains has not been fully leveraged for clinical prediction, especially in scenarios with scarce data (few-shot learning), which is common for rare disease areas or specific patient subgroups. This paper aims to bridge this gap by investigating how transformers and LLMs can enhance clinical prediction accuracy and address the challenges of few-shot learning in this domain.
Methods
The core of this research involves adapting LLMs for clinical prediction tasks. The process begins with serialization, where tabular clinical data (e.g., patient age, lab values, drug class) is converted into natural language sequences that LLMs can process. A simple template, "The {attribute} is {value}," is used for this conversion.
The serialized data is then fed into a frozen LLM encoder. To adapt these LLMs for the specific clinical prediction task, a randomly initialized encoder (which can be transformers or MLPs) is added and fine-tuned. This approach leverages the pre-trained knowledge within the LLM while allowing for task-specific adaptation.
A key aspect is the exploration of different knowledge sources for LLM pre-training. The authors compare domain-agnostic LLMs (trained on general text) with domain-specific LLMs (trained on biomedical or clinical text). They also introduce ClinTaT, a transformer model for tabular data that incorporates improvements over existing models like TabTransformer, including a continuous embedding layer for numerical features.
For training, a multi-loss objective is employed, allowing the model to learn from multiple prediction endpoints simultaneously (e.g., overall survival, progression-free survival, best overall response). This multi-task learning approach is designed to improve generalization by introducing inductive biases.
Datasets
The primary dataset used in this study is the MSK-IMPACT dataset from Memorial Sloan Kettering Cancer Center. This dataset comprises data from 1,479 patients treated with immune checkpoint blockade (ICB) across 16 different cancer types. Each patient's record includes up to 16 biological features (genomic, molecular, clinical, demographic). The dataset is split into a training set of 1,184 patients and a test set of 295 patients. The authors also refer to a public clinical dataset from Chowell et al. (2021) for their pilot study (Figure 1).
Key Insights and Ideas
- LLMs Excel in Few-Shot Learning for Clinical Prediction: The study strongly suggests that LLMs, due to their emergent in-context learning capabilities, are particularly effective in few-shot settings where traditional models struggle due to data scarcity.
- Domain-Specific Pre-training Matters, But Not Always: While domain-specific LLMs (like PubMedBERT) generally outperform domain-agnostic ones, the results also show that a well-trained general LLM (like vanilla BERT) can still achieve competitive performance, suggesting that the depth and breadth of pre-training are crucial.
- Transformers Offer Superior Prognostic Power: The transformer-based models, including ClinTaT, consistently demonstrate improved predictive performance over conventional machine learning methods like logistic regression, random forest, and XGBoost, especially when considering all available training data.
- Multi-Task Learning Enhances Prediction: Combining multiple prediction endpoints (OS, PFS, BOR) into a unified loss objective helps improve the model's ability to forecast treatment outcomes.
- Serialization is Key for LLM Adaptation: The effectiveness of LLMs on tabular data hinges on how well the data is serialized into a format the LLM can understand. The simple template used in this study proved effective.
Key Results
- Treatment Response Prediction: ClinTaT achieved superior performance in predicting responders and non-responders across various cancer types, as indicated by higher Area Under the ROC Curve (AUC) values compared to baselines. For instance, in the pan-cancer setting with all samples, ClinTaT achieved an AUC of 0.815, outperforming XGBoost (0.796) and Random Forest (0.795).
- Survival Prediction (OS & PFS): ClinTaT also showed significantly higher C-indices for predicting Overall Survival (OS) and Progression-Free Survival (PFS) compared to traditional baselines. For pan-cancer OS, ClinTaT achieved a C-index of 0.724, compared to 0.688 for XGBoost.
- Few-Shot Performance: While transformers generally outperform traditional methods, their advantage is less pronounced in very few-shot regimes (e.g., 6 samples). However, even in these scenarios, LLM fine-tuning (specifically PubMedBERT) showed significant improvements over baseline transformers, highlighting the benefit of knowledge transfer. PubMedBERT, fine-tuned with a linear layer, achieved an AUC of 0.649 with only 4 samples, a notable improvement.
Limitations and Future Work
The authors acknowledge several limitations:
- Single Clinical Cohort: The study is based on a single clinical cohort, which may limit the generalizability of the findings to broader patient populations.
- Limited Scope: The focus is primarily on cancer immunotherapy prognosis. Further research is needed to confirm if these LLM-based approaches extend to other clinical prediction tasks.
- Model Comparison: Only a limited set of transformers and LLMs were compared. It's possible that other models could achieve even better performance.
- Integration into Clinical Practice: The ultimate value of these models depends on their successful integration into clinical decision-making processes and their impact on patient care.
Future work could involve:
- Larger and More Diverse Datasets: Expanding the study to include more diverse clinical cohorts and cancer types.
- Exploring More Advanced LLMs: Investigating the use of larger and more sophisticated LLMs (e.g., GPT-3, T5, PubMedGPT) for clinical prediction.
- Optimizing Serialization Techniques: Further research into more advanced methods for serializing tabular data for LLMs.
- Investigating Encoder Architectures: Exploring different encoder architectures beyond simple linear layers or a single transformer block for fine-tuning LLMs.
- Real-World Clinical Validation: Conducting prospective studies to validate the clinical utility and impact of these models in real-world healthcare settings.
Summary updated